

July 14, 2026

Mr. Samit Mattoo

Listing Compliance

BSE Limited,

P J Towers, Dalal Street, Mumbai - 400001, India

Dear Sir / Madam,

Re.: Clarification /Confirmation on news item appearing in “Media/Publication”

Ref.: Email of BSE Limited dated July 14, 2026

With reference to the captioned email, we would like to inform as under that:

- a) there are no negotiations or events which requires disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the **Listing Regulations**”).
- b) the said event (of passing of order by Hon’ble Delhi High Court to temporarily restrict the Company to supply of the cancer drug Ikra™) is not material in terms of the materiality policy of the Company and the provisions of the Listing Regulations.
- c) due to the above news, there has been no material movement in the trading of equity shares of the Company on July 14, 2026. Further, we believe that there is no material impact of this event on the Company.

The Company remains committed to complying with all applicable disclosure requirements under the Listing Regulations and shall keep the stock exchanges informed of any material developments, if and when required.

Please find our response in order.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

Dhaval N. Soni

Company Secretary and Compliance Officer

Membership No. FCS7063

